| Literature DB >> 24381932 |
Clotilde Costa1, Jesús M Paramio1, Mirentxu Santos1.
Abstract
The Rb1 gene was the first bona fide tumor suppressor identified and cloned more than 25 years ago. Since then, a plethora of studies have revealed the functions of pRb and the existence of a sophisticated and strictly regulated pathway that modulates such functional roles. An emerging paradox affecting Rb1 in cancer connects the relatively low number of mutations affecting Rb1 gene in specific human tumors, compared with the widely functional inactivation of pRb in most, if not in all, human cancers. The existence of a retinoblastoma family of proteins pRb, p107, and p130 and their potential unique and overlapping functions as master regulators of cell cycle progression and transcriptional modulation by similar processes, may provide potential clues to explain such conundrum. Here, we will review the development of different genetically engineered mouse models, in particular those affecting stratified epithelia, and how they have offered new avenues to understand the roles of the Rb family members and their targets in the context of tumor development and progression.Entities:
Keywords: E2F; SCC; epidermis; p107; p130; p53; pRb; transgenic mice
Year: 2013 PMID: 24381932 PMCID: PMC3865458 DOI: 10.3389/fonc.2013.00307
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Phenotypic abnormalities observed in germline-ablated mouse models affecting retinoblastoma family members.
| Genotype | Strategy | Lethality | Phenotype | Reference |
|---|---|---|---|---|
| Rb−/− | Germline | Embryonic (13.5) | Developmental defects, increased apoptosis | ( |
| Rb+/− | Germline | Viable | Intermediate lobe pituitary tumors-cell adenomas, c-cell hyperplasia in the thyroid gland | ( |
| Rb+/−; p107−/− | Germline | Viable | Growth retardation, increased mortality rate during the first 3 weeks after birth. Multiple retina dysplastic lesions. No more tumor prone when compared with Rb+/−mice | ( |
| Rb−/−; p107−/− | Germline | Embryonic (11.5) | Accelerated apoptosis in the liver and the central nervous system | ( |
| p107−/−; p130−/− | Germline | Birth | Deregulated chondrocyte growth, defective endochondral bone development, shortened limbs, and neonatal lethality. Impaired terminal differentiation. Decreased number of follicles, developmental delay in hair, whiskers, and tooth germs | ( |
| E2F1−/− | Germline | Viable | Tissue-specific tumor induction, tissue atrophy | ( |
| E2F2−/− | Germline | Viable | T lymphocyte homeostasis defects leading to a lupus-like autoimmune disorder. Negative regulator of the immune response suppressing cellular proliferation of activated lymphocytes | ( |
| E2F3−/− | Germline C57BL/6 | Neonatal | Congestive heart failure. No tumor development | ( |
| E2F3−/− | Germline 129/sv | Embryonic | Proliferation defects | ( |
| E2F1−/−; E2F2−/− | Germline | Viable | Limited lifespan, polyuria, polydipsia, and appeared lethargic prior to death | ( |
| E2F1−/−; E2F3−/− | Germline | Embryonic | Impaired development. Overlapping roles in development/maintenance of several tissues | ( |
| E2F2−/−; E2F3−/− | Germline | Embryonic | Central role of E2F3 in mouse development | ( |
| Rb+/−; E2F3−/− | Germline | Smaller pituitary tumors. Novel tumorigenic lesions | ||
| Rb+/−; E2F1−/− | Germline | Viable | Increase lifespan of Rb+/−. Reduce frequency of pituitary and thyroid tumors | ( |
| Rb+/−; E2F3+/− | Germline 129/Sv | Viable | Little increase lifespan of Rb+/−. Smaller pituitary tumors; E2F3 acts to promote the development of tumors in Rb mutant mice | ( |
| Rb+/−; E2F3+/− | Germline mixed 129/SvXC57BL/6 | Weaning | Increase lifespan of Rb+/− | ( |
| E2F3a−/− | Germline | Viable | No detectable effects. Low penetrance proliferation defect | ( |
| E2F3b−/− | Germline | Viable | No detectable effects | ( |
| E2F3a−/−; E2F1−/− | Germline | Birth (neonatal) | Cartilage defects, proliferation defects | ( |
| DP1−/− | Chimera | Embryonic | Failure of extra-embryonic development | ( |
| Rb−/− | Chimera | Viable | Die 3–11 months of age due to pituitary gland tumors; no retinoblastoma tumor development | ( |
| Rb+/−; p107−/− | Chimera | Viable | Wide spectrum of tumors (pituitary gland, cecum, bone, lymphoid tissue). No retinoblastoma development but retinal dysplasia | ( |
| Rb−/−; p107−/− | Chimera | Viable | Development of retinoblastoma at early age | ( |
| Rb+/−; p130−/− | Chimera | Viable | Thymoma, hepatoma, Leydig cell tumor, insulinoma, and adrenal gland tumor. None of the tumors were seen in more than one animal | ( |
| Rb−/−; p130−/− | Chimera | Viable | Retinoblastoma, pheochromocytoma, and hyperplasia of neuro-endocrine epithelial cells of the bronchus. Early death | ( |
| Rb−/−; E2F3−/− | Chimera | Viable | Suppresses the formation of cataracts while aggravating the retinal dysplasia; dispensable for the development of pRb-deficient pituitary and thyroid tumors; suppresses the pulmonary neuro-endocrine hyperplasia of Rb−/−chimeric mice | ( |
| Rb−/−; E2F4−/− | Chimera | Viable | Reduce incidence of pituitary tumors. Delay development of tumors | ( |
Phenotypic Skin abnormalities observed in mouse models lacking pRb in epidermis.
| Genotype | Strategy | Lethality | Phenotype | Reference |
|---|---|---|---|---|
| Rbf/f; K14cre | Conditional | Viable | Enhanced proliferation, abnormal differentiation. No spontaneous tumor development | ( |
| Rbf/f; K14cre; p130−/− | Conditional | Viable | No differences with Rbf/f; K14cre mice. Altered genomic profile | ( |
| Rbf/f; K14cre; p107−/− | Conditional | Postnatal day 10 | Transplants of newborn skin lead to spontaneous tumors development | ( |
| Rbf/f; K14cre; p53f/f | Conditional | Viable | Develop spontaneous squamous cell carcinoma, accelerated respect p53-deficient mice in epidermis | ( |
| Rbf/f; K14cre; p21−/− | Conditional | High mortality rate | Hyperplasia, hyperkeratosis, inflammatory infiltrates (pnd 30). Phenotype aggravated compared with | ( |
| Rbf/f; K14cre; Ptenf/f | Conditional | Increase mortality at postnatal life | Transplants of newborn skin lead to the development of spontaneous tumors. All die by 2 months of age | ( |
| Rbf/f; K14creERTM | Inducible | Viable | Enhanced proliferation, abnormal differentiation. No spontaneous tumor development | ( |
| Rbf/f; K14creERTM; p107−/− | Inducible | Viable | Aggravated phenotype of Rbf/f; K14cre mice: impair terminal differentiation and abnormal proliferation. Spontaneous squamous cell carcinomas in oral areas. Lifespan 5–6 months due to animal fragility | ( |
| Rbf/f; K14creERTM; E2F1−/− | Inducible | Viable | Impair terminal differentiation and abnormal proliferation. Spontaneous squamous cell carcinomas with high penetrance | ( |